

ABUHB High Cost Drugs Group

Monday 24th October 2022

14:00 on Microsoft Teams



GIG
CYMRU
NHS
WALES

Bwrdd Iechyd Prifysgol
Aneurin Bevan
University Health Board

MEETING NOTES

Item	Published	60 day imp deadline	Implementation Plan reviews	Lead
3	11/8/22	10/10/22	<p>NICE ID3951: Dexamethasone intravitreal implant for treating DMO in people without a psuedophakic lens To be supplied in house for inpatient/day case use. Estimate ~50 pts. Discussed issue that ophthalmology are potentially using this off-label and off-formulary at present. JVG reports not a big spend on this currently (£11k) raises issues around non-NICE use of NICE drugs. Group happy to sign off pending BPA signature</p>	EK to obtain BPA signature
4	6/9/22	5/11/22	<p>NICE ID3841: Ozanimod for treating moderately to severely active ulcerative colitis Oral therapy for end of pathway, could potentially reduce progressions to surgery. Agreed Homecare best potential route for supply.</p>	EK to obtain pharmacist and BPA signature
5	15/9/22	14/11/22	<p>NICE ID1427: Zanbrutinib for treating Waldenstrom's macroglobulinaemia Last line after DRC or bendamustine/rituximab. Predict 5 pts across HB. Oral therapy, to be supplied via Homecare. Cost between 22k and 88k depending on dosage used.</p>	EK to add to formulary.
6	3/10/22	2/12/22	<p>AWMSG: Lacoasamide for epilepsy in children Adjunct oral therapy. Imp form states WP10HP initially and then aims GP to take over (MTC will decide suitability of this but would be in line with other indications for lacosamide in children- also Amber) Tabs on DND list but liquid not. Cost for liquid is £25 for 200ml. Discussed relevance of DND list in this case and decided WP10 best route of supply. Cost impact will depend on dosage and form chosen but if all 30 pts were on max dose of liquid- potential cost could be £55k.</p>	EK to obtain pharmacist and BPA signature.
Item	Published	60 day imp deadline		
	17/8/22	16/10/22	<p>NICE ID1581: Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangitis Some initial engagement with [REDACTED] on this but haven't received form despite repeated chasing.</p>	
Also not received- signed implementation plan for Icosapent Ethyl below. [REDACTED] has completed this plan and HCDIPG approved it pending BPA signature but no BPA will put their signature on it due to ongoing discussions around where the budget for this should sit.				
	10/6/22	9/8/22	<p>NICE ID3831 Icosapent Ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides</p>	